Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

Wring SA, Randolph R, Park S, Abruzzo G, Chen Q, Flattery A, Garrett G, Peel M, Outcalt R, Powell K, Trucksis M, Angulo D, Borroto-Esoda K.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02068-16. doi: 10.1128/AAC.02068-16. Print 2017 Apr.

2.

Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin.

Apgar JM, Wilkening RR, Greenlee ML, Balkovec JM, Flattery AM, Abruzzo GK, Galgoci AM, Giacobbe RA, Gill CJ, Hsu MJ, Liberator P, Misura AS, Motyl M, Nielsen Kahn J, Powles M, Racine F, Dragovic J, Habulihaz B, Fan W, Kirwan R, Lee S, Liu H, Mamai A, Nelson K, Peel M.

Bioorg Med Chem Lett. 2015 Dec 15;25(24):5813-8. doi: 10.1016/j.bmcl.2015.10.011. Epub 2015 Oct 9.

PMID:
26542966
3.

Synthesis and antifungal evaluation of pentyloxyl-diphenylisoxazoloyl pneumocandins and echinocandins.

Singh SB, Herath K, Kahn JN, Mann P, Abruzzo G, Motyl M.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3253-6. doi: 10.1016/j.bmcl.2013.03.115. Epub 2013 Apr 10.

PMID:
23623416
4.

Isolation, structure, and biological activity of Phaeofungin, a cyclic lipodepsipeptide from a Phaeosphaeria sp. Using the Genome-Wide Candida albicans Fitness Test.

Singh SB, Ondeyka J, Harris G, Herath K, Zink D, Vicente F, Bills G, Collado J, Platas G, González del Val A, Martin J, Reyes F, Wang H, Kahn JN, Galuska S, Giacobbe R, Abruzzo G, Roemer T, Xu D.

J Nat Prod. 2013 Mar 22;76(3):334-45. doi: 10.1021/np300704s. Epub 2012 Dec 24.

PMID:
23259972
5.

Antifungal spectrum, in vivo efficacy, and structure-activity relationship of ilicicolin h.

Singh SB, Liu W, Li X, Chen T, Shafiee A, Card D, Abruzzo G, Flattery A, Gill C, Thompson JR, Rosenbach M, Dreikorn S, Hornak V, Meinz M, Kurtz M, Kelly R, Onishi JC.

ACS Med Chem Lett. 2012 Sep 7;3(10):814-7. doi: 10.1021/ml300173e. eCollection 2012 Oct 11.

6.

Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis.

Flattery AM, Hickey E, Gill CJ, Powles MA, Misura AS, Galgoci AM, Ellis JD, Zhang R, Sandhu P, Ronan J, Abruzzo GK.

Antimicrob Agents Chemother. 2011 Jul;55(7):3491-7. doi: 10.1128/AAC.01328-10. Epub 2011 Apr 25.

7.

Isolation, structure elucidation, and biological activity of virgineone from Lachnum Wirgineum using the genome-wide Candida albicans fitness test.

Ondeyka J, Harris G, Zink D, Basilio A, Vicente F, Bills G, Platas G, Collado J, Gonzáez A, de la Cruz M, Martin J, Kahn JN, Galuska S, Giacobbe R, Abruzzo G, Hickey E, Liberator P, Jiang B, Xu D, Roemer T, Singh SB.

J Nat Prod. 2009 Jan;72(1):136-41. doi: 10.1021/np800511r.

PMID:
19115836
8.

Isolation, structure and biological activity of phomafungin, a cyclic lipodepsipeptide from a widespread tropical Phoma sp.

Herath K, Harris G, Jayasuriya H, Zink D, Smith S, Vicente F, Bills G, Collado J, González A, Jiang B, Kahn JN, Galuska S, Giacobbe R, Abruzzo G, Hickey E, Liberator P, Xu D, Roemer T, Singh SB.

Bioorg Med Chem. 2009 Feb 1;17(3):1361-9. doi: 10.1016/j.bmc.2008.12.009. Epub 2008 Dec 14.

PMID:
19112025
9.

PAP inhibitor with in vivo efficacy identified by Candida albicans genetic profiling of natural products.

Jiang B, Xu D, Allocco J, Parish C, Davison J, Veillette K, Sillaots S, Hu W, Rodriguez-Suarez R, Trosok S, Zhang L, Li Y, Rahkhoodaee F, Ransom T, Martel N, Wang H, Gauvin D, Wiltsie J, Wisniewski D, Salowe S, Kahn JN, Hsu MJ, Giacobbe R, Abruzzo G, Flattery A, Gill C, Youngman P, Wilson K, Bills G, Platas G, Pelaez F, Diez MT, Kauffman S, Becker J, Harris G, Liberator P, Roemer T.

Chem Biol. 2008 Apr;15(4):363-74. doi: 10.1016/j.chembiol.2008.02.016.

10.

In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection.

Gill CJ, Abruzzo GK, Flattery AM, Misura AS, Bartizal K, Hickey EJ.

Antimicrob Agents Chemother. 2007 Sep;51(9):3434-6. Epub 2007 Jul 2.

11.

Efficacy of caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans.

Bowman JC, Abruzzo GK, Flattery AM, Gill CJ, Hickey EJ, Hsu MJ, Kahn JN, Liberator PA, Misura AS, Pelak BA, Wang TC, Douglas CM.

Antimicrob Agents Chemother. 2006 Dec;50(12):4202-5. Epub 2006 Oct 2.

12.

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS.

Antimicrob Agents Chemother. 2005 Aug;49(8):3264-73.

13.

A new ene-triyne antibiotic from the fungus Baeospora myosura.

Parish CA, Huber J, Baxter J, González A, Collado J, Platas G, Diez MT, Vicente F, Dorso K, Abruzzo G, Wilson K.

J Nat Prod. 2004 Nov;67(11):1900-2.

PMID:
15568786
14.

Inactivation of Kex2p diminishes the virulence of Candida albicans.

Newport G, Kuo A, Flattery A, Gill C, Blake JJ, Kurtz MB, Abruzzo GK, Agabian N.

J Biol Chem. 2003 Jan 17;278(3):1713-20. Epub 2002 Nov 4.

15.

Arundifungin, a novel antifungal compound produced by fungi: biological activity and taxonomy of the producing organisms.

Cabello MA, Platas G, Collado J, Díez MT, Martín I, Vicente F, Meinz M, Onishi JC, Douglas C, Thompson J, Kurtz MB, Schwartz RE, Bills GF, Giacobbe RA, Abruzzo GK, Flattery AM, Kong L, Peláez F.

Int Microbiol. 2001 Jun;4(2):93-102.

PMID:
11770831
16.

Antimicrobial activity of ergokonin A from Trichoderma longibrachiatum.

Vicente MF, Cabello A, Platas G, Basilio A, Díez MT, Dreikorn S, Giacobbe RA, Onishi JC, Meinz M, Kurtz MB, Rosenbach M, Thompson J, Abruzzo G, Flattery A, Kong L, Tsipouras A, Wilson KE, Peláez F.

J Appl Microbiol. 2001 Nov;91(5):806-13.

17.

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.

Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM.

Antimicrob Agents Chemother. 2001 Dec;45(12):3474-81.

18.

The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms.

Peláez F, Cabello A, Platas G, Díez MT, González del Val A, Basilio A, Martán I, Vicente F, Bills GE, Giacobbe RA, Schwartz RE, Onish JC, Meinz MS, Abruzzo GK, Flattery AM, Kong L, Kurtz MB.

Syst Appl Microbiol. 2000 Oct;23(3):333-43.

PMID:
11108011
19.

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.

Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, Pikounis VB, Bartizal K, Rosen H.

Antimicrob Agents Chemother. 2000 Sep;44(9):2310-8.

20.

Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Onishi J, Meinz M, Thompson J, Curotto J, Dreikorn S, Rosenbach M, Douglas C, Abruzzo G, Flattery A, Kong L, Cabello A, Vicente F, Pelaez F, Diez MT, Martin I, Bills G, Giacobbe R, Dombrowski A, Schwartz R, Morris S, Harris G, Tsipouras A, Wilson K, Kurtz MB.

Antimicrob Agents Chemother. 2000 Feb;44(2):368-77.

21.

Identification and purification of the reconstitutively active glutamine carrier from rat kidney mitochondria.

Indiveri C, Abruzzo G, Stipani I, Palmieri F.

Biochem J. 1998 Jul 15;333 ( Pt 2):285-90.

22.

Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase.

Mandala SM, Thornton RA, Milligan J, Rosenbach M, Garcia-Calvo M, Bull HG, Harris G, Abruzzo GK, Flattery AM, Gill CJ, Bartizal K, Dreikorn S, Kurtz MB.

J Biol Chem. 1998 Jun 12;273(24):14942-9.

23.

Antibacterial activity of lonchocarpol A.

Salvatore MJ, King AB, Graham AC, Onishi HR, Bartizal KF, Abruzzo GK, Gill CJ, Ramjit HG, Pitzenberger SM, Witherup KM.

J Nat Prod. 1998 May;61(5):640-2.

PMID:
9599265
24.

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, Li W, Abruzzo GK, Flattery A, Bartizal K, Mitchell A, Kurtz MB.

Antimicrob Agents Chemother. 1997 Nov;41(11):2471-9.

25.

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, Balkovec JM, Bouffard AF, Dropinski JF, Rosen H, Kropp H, Bartizal K.

Antimicrob Agents Chemother. 1997 Nov;41(11):2333-8.

26.

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, Smith JG, Leighton CE, Bouffard A, Dropinski JF, Balkovec J.

Antimicrob Agents Chemother. 1997 Nov;41(11):2326-32.

27.

Evaluation of experimental therapeutics in a new mouse model of Helicobacter felis utilizing 16S rRNA polymerase chain reaction for detection.

Smith JG, Kong L, Abruzzo GK, Gill CJ, Flattery AM, Scott PM, Silver L, Kropp H, Bartizal K.

Scand J Gastroenterol. 1997 Apr;32(4):297-302.

PMID:
9140149
28.

Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

Kurtz MB, Abruzzo G, Flattery A, Bartizal K, Marrinan JA, Li W, Milligan J, Nollstadt K, Douglas CM.

Infect Immun. 1996 Aug;64(8):3244-51.

29.

New model of oropharyngeal and gastrointestinal colonization by Candida albicans in CD4+ T-cell-deficient mice for evaluation of antifungal agents.

Flattery AM, Abruzzo GK, Gill CJ, Smith JG, Bartizal K.

Antimicrob Agents Chemother. 1996 Jul;40(7):1604-9.

30.

Carbazate as a glycine bioisostere in restricticin.

VanMiddlesworth F, Milligan J, Bartizal K, Dufresne C, Onishi J, Abruzzo G, Patchett A, Wilson K.

J Antibiot (Tokyo). 1996 Mar;49(3):329-31. No abstract available.

31.

A sensitive and specific PCR method to detect Helicobacter felis in a conventional mouse model.

Kong L, Smith JG, Bramhill D, Abruzzo GK, Bonfiglio C, Cioffe C, Flattery AM, Gill CJ, Lynch L, Scott PM, Silver L, Thompson C, Kropp H, Bartizal K.

Clin Diagn Lab Immunol. 1996 Jan;3(1):73-8.

32.

PCR detection of colonization by Helicobacter pylori in conventional, euthymic mice based on the 16S ribosomal gene sequence.

Smith JG, Kong L, Abruzzo GK, Gill CJ, Flattery AM, Scott PM, Bramhill D, Cioffe C, Thompson CM, Bartizal K.

Clin Diagn Lab Immunol. 1996 Jan;3(1):66-72.

33.

In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin.

Gill CJ, Abruzzo GK, Flattery AM, Smith JG, Jackson J, Kong L, Wilkening R, Shankaran K, Kropp H, Bartizal K.

J Antibiot (Tokyo). 1995 Oct;48(10):1141-7.

34.

Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.

Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Krupa D, Pikounis VB, Kropp H, Bartizal K.

Antimicrob Agents Chemother. 1995 May;39(5):1077-81.

35.

In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373.

Bartizal K, Scott T, Abruzzo GK, Gill CJ, Pacholok C, Lynch L, Kropp H.

Antimicrob Agents Chemother. 1995 May;39(5):1070-6.

36.

Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

Bouffard FA, Zambias RA, Dropinski JF, Balkovec JM, Hammond ML, Abruzzo GK, Bartizal KF, Marrinan JA, Kurtz MB, McFadden DC, et al.

J Med Chem. 1994 Jan 21;37(2):222-5. No abstract available.

PMID:
8295208
37.

Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species.

Schmatz DM, Abruzzo G, Powles MA, McFadden DC, Balkovec JM, Black RM, Nollstadt K, Bartizal K.

J Antibiot (Tokyo). 1992 Dec;45(12):1886-91.

38.

In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.

Bartizal K, Abruzzo G, Trainor C, Krupa D, Nollstadt K, Schmatz D, Schwartz R, Hammond M, Balkovec J, Vanmiddlesworth F.

Antimicrob Agents Chemother. 1992 Aug;36(8):1648-57.

39.

Preparation and structure-activity relationships of simplified analogues of the antifungal agent cilofungin: a total synthesis approach.

Zambias RA, Hammond ML, Heck JV, Bartizal K, Trainor C, Abruzzo G, Schmatz DM, Nollstadt KM.

J Med Chem. 1992 Jul 24;35(15):2843-55.

PMID:
1495015
40.

Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP).

Balkovec JM, Black RM, Hammond ML, Heck JV, Zambias RA, Abruzzo G, Bartizal K, Kropp H, Trainor C, Schwartz RE, et al.

J Med Chem. 1992 Jan;35(1):194-8. No abstract available.

PMID:
1732529
41.

Restricticin, a novel glycine-containing antifungal agent.

Schwartz RE, Dufresne C, Flor JE, Kempf AJ, Wilson KE, Lam T, Onishi J, Milligan J, Fromtling RA, Abruzzo GK, et al.

J Antibiot (Tokyo). 1991 May;44(5):463-71.

42.

The "Kergin pneumonectomy".

Gozzetti G, Mastrorilli M, Bragaglia RB, D'Abruzzo GC, Romualdi A, Villani S, Liberatore GL, Spolaore R.

World J Surg. 1990 Sep-Oct;14(5):624-7.

PMID:
2238663
43.

Lack of cross-resistance between efrotomycin and antibacterial agents used in the therapy of human and animal infections.

Jacks TM, Frazier EG, Abruzzo GK, Graham AC, Fromtling RA.

Methods Find Exp Clin Pharmacol. 1989 Nov;11(11):697-701.

PMID:
2695724
44.
45.

L-658,310, a new injectable cephalosporin. III. Experimental chemotherapeutics and pharmacokinetics in laboratory animals.

Gilfillan EC, Pelak BA, Weissberger BA, Abruzzo GK, Fromtling RA, Bland JA, Hadley SK, Gadebusch HH.

J Antibiot (Tokyo). 1989 May;42(5):815-22.

46.

L-658,310, a new injectable cephalosporin. I. In vitro antibacterial properties.

Weissberger BA, Abruzzo GK, Fromtling RA, Gill C, Ponticas S, Valiant ME, Shungu DL, Gadebusch HH.

J Antibiot (Tokyo). 1989 May;42(5):795-806.

47.
48.

L-656,575 (OCP-9-176): a novel oxacephem. In vitro activity against aerobic and anaerobic clinical bacterial isolates.

Weissberger B, Abruzzo GK, Fromtling RA, Valiant ME, Shungu DL, Gadebusch HH.

J Antibiot (Tokyo). 1988 Aug;41(8):1130-6.

49.

Renal pathology and spleen cell chemiluminescence of mice infected with a wild-type and a low-virulence mutant of Candida albicans.

Fromtling RA, Abruzzo GK, Edison A, Manning-Zweerink M.

Zentralbl Bakteriol Mikrobiol Hyg A. 1988 May;268(3):405-15.

PMID:
3043983
50.

Supplemental Content

Loading ...
Support Center